JP Morgan Chase
IRLA

JP Morgan Chase’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

JP Morgan Chase’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Hold
2
– – ﹤0.01% 7689
2026
Q1 		$48 Hold
2
– – ﹤0.01% 7366
2025
Q4 		$1.57K Hold
2
– – ﹤0.01% 6980
2025
Q3 		$764 Hold
2
– – ﹤0.01% 7014
2025
Q2 		$774 Sell
2
-1
-33% -$229 ﹤0.01% 6650
2025
Q1 		$728 Hold
3
– – ﹤0.01% 6663
2024
Q4 		$1.02K Hold
3
– – ﹤0.01% 6730
2024
Q3 		$425 Buy
3
+1
+50% +$143 ﹤0.01% 6818
2024
Q2 		$352 Hold
2
– – ﹤0.01% 6723
2024
Q1 		$497 Hold
2
– – ﹤0.01% 6719
2023
Q4 		$492 Hold
2
– – ﹤0.01% 6927
2023
Q3 		$525 Hold
2
– – ﹤0.01% 6720
2023
Q2 		$706 Hold
2
– – ﹤0.01% 6506
2023
Q1 		$1K Hold
2
– – ﹤0.01% 6540
2022
Q4 		$0 Sell
2
-1,162
-100% -$194K ﹤0.01% 6911
2022
Q3 		$310K Sell
1,164
-1,671
-59% -$636K ﹤0.01% 4737
2022
Q2 		$1.26M Sell
2,835
-117
-4% -$82.7K ﹤0.01% 3910
2022
Q1 		$3.65M Buy
2,952
+2,901
+5,688% +$3.95M ﹤0.01% 3264
2021
Q4 		$128K Sell
51
-17
-25% -$104K ﹤0.01% 5576
2021
Q3 		$1.24M Buy
68
+7
+11% +$111K ﹤0.01% 4148
2021
Q2 		$645K Buy
61
+17
+39% +$143K ﹤0.01% 4543
2021
Q1 		$321K Sell
44
-42
-49% -$302K ﹤0.01% 4935
2020
Q4 		$477K Buy
86
+32
+59% +$284K ﹤0.01% 4394
2020
Q3 		$539K Buy
54
+2
+4% +$18.2K ﹤0.01% 3948
2020
Q2 		$481K Sell
52
-20
-28% -$183K ﹤0.01% 3870
2020
Q1 		$654K Buy
72
+12
+20% +$118K ﹤0.01% 3684
2019
Q4 		$673K Buy
60
+44
+275% +$265K ﹤0.01% 4088
2019
Q3 		$82K Buy
16
+6
+60% +$36.9K ﹤0.01% 4972
2019
Q2 		$78K Buy
+10
New +$59.7K ﹤0.01% 5014

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase's IRLA Position: Q2 2026 in Review

JP Morgan Chase held its IRulya Therapeutics Inc. Common Stock (IRLA) position steady in Q2 2026 at 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #7689.

JP Morgan Chase first reported a position in IRLA in Q2 2019 and has held it in 29 quarters since. The position peaked at $3.65M in Q1 2022. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • JP Morgan Chase held 2 shares of IRulya Therapeutics Inc. Common Stock worth $2 as of Q2 2026.
  • JP Morgan Chase left its IRulya Therapeutics Inc. Common Stock share count unchanged in Q2 2026.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7689 holding.
  • JP Morgan Chase first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and has held it in 29 quarters since.
  • JP Morgan Chase's IRulya Therapeutics Inc. Common Stock position peaked at $3.65M in Q1 2022.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.